Popular GLP-1 medications such as Ozempic may carry an unexpected link to a lower risk of epilepsy in people with type 2 diabetes.

Xenon Pharmaceuticals Inc. ( XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 10:00 AM EST ...

The Neurology Advisor Team spoke with Shilpa Reddy, MD, MMHC at AES 2025 in Atlanta, Georgia. Neurology Advisor: “Can you describe your work in neuromodulation?” ...

Midazolam for refractory status epilepticus reduces 30-day mortality and complications versus propofol, though long-term outcomes are similar.

People with drug-resistant epilepsy have had few other options, but Neuropace Inc. appears on target to provide an alternative. The Nautilus trial of its responsive neurostimulation system for ...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...

NeuroPace (NPCE) announced the presentation at the American Epilepsy Society meeting of preliminary 18-month safety and effectiveness results from ...

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

ATLANTA -- In health matters it's not often that older people do better than their younger peers, but seizure disorders may be an example, suggested a cross-sectional study.

Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study ...

Praxis Precision stock rallies on positive EMBOLD results, FDA meeting confirmed, and analyst increases probability of ...

Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of ...